SERB Pharmaceuticals acquiert l’Aurlumyn (Iloprost IV) auprès de CiVi Biopharma Holdings Inc.

Georgio Naffaa
Tagged:

Mayer Brown a conseillé SERB Pharmaceuticals dans le cadre de la structuration de l’acquisition de Aurlumyn® (iloprost IV) auprès de CiVi Biopharma Holdings Inc.SERB Pharmaceuticals a…

This content is for members only.
Login Join Now

Author: Georgio Naffaa

…

This content is for members only.
Login Join Now